Eculizumab
Soliris (eculizumab) is an antibody pharmaceutical. Eculizumab was first approved as Soliris on 2007-03-16. It is used to treat atypical hemolytic uremic syndrome and paroxysmal hemoglobinuria in the USA. It has been approved in Europe to treat paroxysmal hemoglobinuria. The pharmaceutical is active against complement C5.
Trade Name | Soliris |
---|---|
Common Name | Eculizumab |
Indication | atypical hemolytic uremic syndrome, paroxysmal hemoglobinuria |
Drug Class | Monoclonal antibodies: humanized, immunomodulating |
